Table 2.

Age correlation with DAT activity, measured with FP-CIT SPECT and FE-PE2I PET

	HC, n = 28			PS, n = 22
	All R	All p	Female/male R	All R	All p	Low DAT/normal DAT R
Caudate
FP-CIT, SUR	− 0.496	0.007	− 0.599*/− 0.360†	− 0.354	0.107	− 0.565*/− 0.396 †
FE-PE2I, BPND	− 0.577	0.001	− 0.803**/− 0.402†	−0.569	0.006	− 0.679**/− 0.965**
FE-PE2I, SUVR	− 0.502	0.007	− 0.796**/− 0.295†	− 0.546	0.009	− 0.649**/− 0.970**
Putamen
FP-CIT, SUR	− 0.400	0.035	− 0.543†/− 0.161†	− 0.207	0.355	− 0.612**/− 0.544 †
FE-PE2I, BPND	− 0.540	0.003	− 0.697**/− 0.395†	− 0.153	0.497	− 0.475 † /− 0.564 †
FE-PE2I, SUVR	− 0.430	0.022	− 0.556*/− 0.287†	− 0.150	0.505	− 0.433 † /− 0.698 †
Striatum
FP-CIT, SUR	− 0.449	0.016	− 0.567*/− 0.280†	− 0.267	0.230	− 0.602*/− 0.496 †
FE-PE2I, BPND	− 0.588	0.001	− 0.780**/− 0.424†	− 0.328	0.136	− 0.610**/− 0.832 †
FE-PE2I, SUVR	− 0.480	0.010	− 0.675*/− 0.302†	− 0.316	0.153	− 0.568*/− 0.916*
SN
FE-PE2I, BPND	0.071	0.719	0.246 † /− 0.117 †	− 0.175	0.436	− 0.333 † /− 0.221 †
FE-PE2I, SUVR	0.058	0.768	0.199†/− 0.460†	− 0.152	0.500	− 0.273 † /− 0.139 †

Correlations are calculated for mean DAT availability values in the respective compartments (averaged between the left and right hemispheres). Patients with low DAT n = 17, patients with normal DAT n = 5

SUR specific uptake ratio, BP_ND binding potential relative to non-displaceable binding, SUVR specific uptake value ratio, SN substantia nigra, HC healthy controls, PS parkinsonian syndrome

*Correlation is significant at the 0.05 level (two-tailed)

**Correlation is significant at the 0.01 level (two-tailed)

^†Correlation is not significant (two-tailed)